ASCO 2011: Phase II Cabozantinib Trial in Patients with Advanced Solid Tumors and Bone Metastases

Article

Data from a phase II study of cabozantinib (XL184) in patients with advanced solid tumors show that the drug has activity in both bone and soft tissue. The study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including breast, lung, ovarian, and prostate.

Data from a phase II study of cabozantinib (XL184) in patients with advanced solid tumors show that the drug has activity in both bone and soft tissue. The study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including breast, lung, ovarian, and prostate.

Osteoplastic Metastasis of Prostate Cancer in Choline PET/CT

The data from the abstract, “Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors” (J Clin Oncol 29: 2011 [suppl; abstr 3010]) will be presented at this year's annual meeting of the American Society of Clinical Oncology (ASCO) during the oral session "Developmental Therapeutics-Experimental Therapeutics" on Sunday June 5, 2011.

Cabozantinib is an oral, inhibitor of the tyrosine kinases, Met and vascular endothelial growth factor receptor 2 (VEGFR2). All patients in the study had progressive disease including bone metastases. The most common side effects were fatigue, hand-foot syndrome, and hypertension. Of 68 brain metastases patients, 59 showed a partial or complete response. Notable, the response was accompanied by symptom improvement.

XL184 has also been highlighted as an interesting entity to watch for ovarian cancer and prostate cancers with bone disease. In this study, 24% of ovarian cancer patients responded to treatment compared to 5–14% of patients with other tumor types. 

In prostate cancer patients, an “unprecedented bone scan improvement” was observed. Based upon these results, Exelixis, the company that is developing cabozantinib will expand the prostate and ovarian cancer cohorts for this trial and also plans to initiate the first pivotal trial in prostate cancer by the end of this year.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content